Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Guggenheim

Guggenheim upgraded shares of Neumora Therapeutics (NASDAQ:NMRA) from a neutral rating to a buy rating in a research report released on Monday morning, Marketbeat.com reports. They currently have $14.00 target price on the stock.

NMRA has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Wednesday, October 8th. Mizuho boosted their price target on Neumora Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. Finally, JPMorgan Chase & Co. cut shares of Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Tuesday, September 16th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.38.

Neumora Therapeutics Trading Down 3.5%

Shares of NMRA opened at $2.50 on Monday. The stock has a fifty day moving average of $1.82 and a two-hundred day moving average of $1.33. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.54 and a current ratio of 10.54. The company has a market capitalization of $404.88 million, a PE ratio of -1.59 and a beta of 2.92. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $14.09.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.05. As a group, analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

Insider Buying and Selling at Neumora Therapeutics

In other Neumora Therapeutics news, Director Kristina Burow purchased 1,915,700 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The stock was purchased at an average cost of $2.61 per share, with a total value of $4,999,977.00. Following the transaction, the director owned 6,046,907 shares in the company, valued at approximately $15,782,427.27. This trade represents a 46.37% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Arch Venture Partners Xii, Llc purchased 1,915,700 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were acquired at an average cost of $2.61 per share, with a total value of $4,999,977.00. Following the completion of the transaction, the insider owned 6,046,907 shares in the company, valued at $15,782,427.27. This trade represents a 46.37% increase in their position. The disclosure for this purchase is available in the SEC filing. 26.80% of the stock is owned by insiders.

Institutional Trading of Neumora Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NMRA. CWM LLC boosted its position in Neumora Therapeutics by 7,124.4% during the 1st quarter. CWM LLC now owns 25,213 shares of the company’s stock worth $25,000 after purchasing an additional 24,864 shares during the period. Jump Financial LLC purchased a new stake in Neumora Therapeutics during the 1st quarter worth $25,000. Legacy Private Trust Co. purchased a new stake in Neumora Therapeutics during the 3rd quarter worth $25,000. Catalyst Funds Management Pty Ltd purchased a new stake in Neumora Therapeutics during the 2nd quarter worth $29,000. Finally, Aigen Investment Management LP purchased a new stake in Neumora Therapeutics during the 1st quarter worth $36,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.